Loading organizations...
§ Private Profile · Chalfont, PA, USA
Pharmacogenetic testing for personalized mental health. Genecept Assay & Genomind PGx analyze genetic factors to improve psychiatric care.
Genomind is a King of Prussia, Pennsylvania-based healthcare company that provides pharmacogenetic testing and a precision health platform to guide personalized mental health treatments. The organization develops saliva-based diagnostic tests, such as the Genecept Assay and Genomind PGx, which analyze genetic factors and drug interactions to assist psychiatrists and neurologists in reducing trial-and-error prescribing. To support its clinical operations and direct-to-consumer offerings like the Mental Health Map, the enterprise has raised nearly $80 million in total funding across multiple equity rounds. The company's financial backing includes a $5 million Series A and a recent $4.9 million Series D initial close, with capital provided by lead investors such as Claritas Capital and the Dozoretz Trust. Currently led by chief executive officer Shawn Patrick O’Brien, Genomind was originally founded in 2009 by Ronald I. Dozoretz and Jay Lombard.
Genomind has raised $11.0M across 2 funding rounds.
Genomind has raised $11.0M in total across 2 funding rounds.
Genomind has raised $11.0M across 2 funding rounds. Most recently, it raised $6.0M Other Equity in September 2015.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 24, 2015 | $6M Venture Round | Claritas Capital | — | Announced |
| Apr 9, 2014 | $5M Series A | Theresa Sexton | — | Announced |
Genomind has raised $11.0M in total across 2 funding rounds.
Genomind's investors include Claritas Capital, Theresa Sexton.